Randomized controlled azathioprine withdrawal after more than two years treatment in Crohn's disease: Increased relapse rate the following year

Alimentary Pharmacology and Therapeutics

Volumn 19, Issue 11, 2004, Pages 1147-1152

  Vilien, M ^a,g   Dahlerup, J F ^b   Munck, L K ^c   Norregaard P ^d   Gronbaek K ^e   Fallingborg, J ^f  

^a West Zealand Hospital   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c KØGE HOSPITAL   (Denmark)

^d HVIDOVRE HOSPITAL   (Denmark)

^e Rigshospitalet   (Denmark)

^f AALBORG UNIVERSITY HOSPITAL   (Denmark)

^g NONE   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DOSE RESPONSE; DRUG EFFECT; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; REMISSION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADULT; AGED; AZATHIOPRINE; CROHN DISEASE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; RECURRENCE;

EID: 2942612097     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.01944.x     Document Type: Article

References (22)

1. Brooke BN, Hoffman DC, Swarbrick ET. Azathioprine for Crohn's disease. Lancet 1969; 2: 612-4.
2. Willoughby JM, Beckett J, Kumar PJ, Dawson AM. Controlled trial of azathioprine in Crohn's disease. Lancet 1971; 2: 944-7.
3. Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev 2000; 2: CD000545.
4. Pearson DC, May GR, Fick G, Sutherland LR. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev 2000; 2: CD000067.
5. Sandborn WJ, Tremaine WJ, Wolf DC, et al. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. Gastroenterol 1999; 117: 527-35.
6. Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Int Med 1989; 111: 641-9.
7. Bouhnik Y, Léman M, Jens-Yves M, et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 1996; 347: 215-9.
8. Kim PS, Zlatanic J, Korelitz BI, Gleim GW. Optimum duration of treatment with 6-mercaptopurine for Crohn's disease. Am J Gastroenterol 1999; 94: 3254-7.
9. Sandborn WJ. Azathioprine: state of the art in inflammatory bowel disease. Scand J Gastroenterol 1998; 33(Suppl. 225): 92-9.
10. Kaskas BA, Louis E, Hindorf U, et al. Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine. Gut 2003; 52: 140-2.
11. Summers RW, Switz DM, Sessions JT, et al. National cooperative Crohn's disease study: Results of drug treatment. Gastroenterology 1979; 77: 847-69.
12. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National cooperative Crohn's disease study. Gastroenterology 1976; 70: 439-44.
13. Machin D, Gardner MJ. Calculating confidence intervals for survival time analyses. In: Gardner, MJ, Altman, DG, eds. Statistics with Confidence - Confidence Intervals and Statistical Guidelines. London: BMJ, 1989: 64-70.
14. Agresti A, Coull BA. Approximate is better than "Exact" for interval estimation of binomial proportions. The American Statistician 1998; 52: 119-26.
15. SAS Institute Inc. SAS Campus Drive. Cary, North Carolina: SAS Institute Inc, 27513.
16. O'Donoughe DP, Dawson AM, Powell-Tuck J, Brown RL, Lennard-Jones JE. Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease. Lancet 1978; 2: 955-7.
17. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease. Gut 2000; 50: 485-9.
18. Rosenberg JL, Levin B, Wall AJ, Kirsner JB. A controlled trial of azathioprine in Crohn's disease. Am J Dig Dis 1975; 20: 721-6.
19. Candy S, Wright JP, Gerber M, Adams G, Gerig M, Goodman R. A double blind controlled study of azathioprine in the treatment and maintenance of remission in Crohn's disease. Gut 1995; 37: 674-8.
20. Present DH, Korelitz BI, Wisch N, Glass JI, Sacher DB, Pasternack BS. Treatment of Crohn's disease with 6-mercaptopurine. NEJM 1980; 302: 981-7.
21. Wallace TM, Veldhuyzen van Zantan SJ. Frequency of use and standards of care for the use of azathioprine and 6-mercaptopurine in the treatment of inflammatory bowel disease: a systematic review of the literature and survey of Canadian gastroenterologists. Can J Gastroenterol 2001; 15: 21-8.
22. Dubinsky MC, Yang H, Hassard PV, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002; 122: 901-15.